Published in Vaccine Weekly, February 20th, 2002
"Pneumococcal surface adhesin A (PsaA), a common protein expressed on all 90 pneumococcal serotypes, is a vaccine candidate," explained Dr. Scott E. Johnson and colleagues at the U.S. Centers for Disease Control and Prevention in Atlanta, Georgia.
PsaA peptides were highly immunogenic in a murine model, Johnson and coauthors reported.
The researchers evaluated the efficacy of three PsaA peptides in mice exposed to pneumococcal pathogens. They tested the effects of lipidating...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.